CSL Behring said on Tuesday that the U.S. Food and Drug Administration (FDA) approved a 50mL/10gm prefilled syringe for Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid).

The new 50mL/10gm prefilled syringe is expected to be available in early 2024. Hizentra is currently available in 5mL/1gm, 10mL/2gm, and 20mL/4gm prefilled syringes as well as in 5mL/1gm, 10mL/2gm ...

(2023-04-18 | OTCQX:CSLLY) CSL Behring Receives FDA Approval for Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) 50mL Prefilled Syringe Stockhouse.com uses cookies on this site. By ...

--Global biotechnology leader CSL Behring today announced the U.S. Food and Drug Administration approved a 50 mL/10gm prefilled syringe for Hizentra ®. CSL Behring now offers a full range of ...

Hizentra ® (immune globulin subcutaneous [human] 20% Liquid) is now available in a new 10g/50mL prefilled syringe.. Hizentra is indicated:. As replacement therapy for primary immunodeficiency (PI ...

From left to right, devices tested included commercial 500-mL compressible plastic bottle with splash guard (splash guard), a 10-mL syringe, a 10-mL syringe with a 14-ga catheter( 10-mL syringe ...